Coagulopathy in COVID-19 and anticoagulation clinical trials

H Zhang, Q Lao, J Zhang, J Zhu - Best Practice & Research Clinical …, 2022 - Elsevier
Severe acute respiratory disease coronavirus 2 (SARS-COV-2) first emerged in Wuhan,
China, in December 2019 and has caused a global pandemic of a scale unprecedented in …

Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial

T Shah, M McCarthy, I Nasir, H Archer, E Ragheb… - BMJ open, 2023 - bmjopen.bmj.com
Objective To evaluate the effect of colchicine and high-intensity rosuvastatin in addition to
standard of care on the progression of COVID-19 disease in hospitalised patients. Design A …

Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials

HA Cheema, U Jafar, A Shahid, W Masood… - BMJ open, 2024 - bmjopen.bmj.com
Objectives We conducted an updated systematic review and meta-analysis to investigate the
effect of colchicine treatment on clinical outcomes in patients with COVID-19. Design …

In-syringe dispersive solid phase filter extraction cleanup followed by liquid chromatography-triple quadrupole mass spectrometry for fast determination of colchicine …

M Qian, Z Chen, X Tao, F Yao, X Xu - Journal of Pharmaceutical and …, 2023 - Elsevier
As an effective treatment for acute gouty arthritis and cardiovascular disease, colchicine is
also a toxic alkaloid and may cause poisoning or even death in overdose. The study of …

[HTML][HTML] Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical …

LP Bonifácio, E Ramacciotti, LB Agati… - Revista da Sociedade …, 2023 - SciELO Brasil
Background: Cases of coronavirus disease 2019 (COVID-19) requiring hospitalization
continue to appear in vulnerable populations, highlighting the importance of novel …

FRAGILE-COLCOVID19: a clinical trial based on early administration of an oral combination of colchicine and prednisone in elderly patients with COVID-19 in geriatric …

J Hernández-Rodríguez, J Durán-Sanclemente… - Clinical Drug …, 2022 - Springer
Background Unprotected and fragile elderly people in nursing homes experienced the
highest mortality rates during the initial coronavirus disease 2019 (COVID-19) pandemic …

Clinical and imaging features of patients with COVID-19 in a double-center cohort study

MG Jelodar, M Nadershahbaz, S Mirzaei… - The Journal of Infection …, 2024 - jidc.org
Introduction: There is extensive published data on coronavirus disease 2019 (COVID-19).
However, information on the effective factors that improve the pulmonary involvement of …

Natural compounds from medicinal plants against COVID-19

A Kolodnitsky, N Ionov, I Gravel… - Exploration of Drug …, 2023 - explorationpub.com
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), known to cause the
coronavirus disease 2019 (COVID-19), was declared a pandemic in early 2020. During the …

[PDF][PDF] Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical …

MZ Haroon, U Farooq, S Ashraf, S Zeb… - Journal of Physiology …, 2022 - researchgate.net
Systemic inflammation is a hallmark of severe coronavirus disease-19 (COVID-19). Anti-
inflammatory therapy is considered crucial to modulate the hyperinflammatory response …

Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS

SF Nabavi, A Sahebnasagh, A Shahbazi… - Current medicinal …, 2023 - ingentaconnect.com
Given the importance of COVID-19-induced ARDS, recently, researchers have strived to
determine underlying mechanisms involved in the inflammatory responses. In this regard …